Hinova Pharmaceuticals (SHSE:688302) Tax Provision: ¥-0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688302 Hinova Pharmaceuticals Inc SHSE:688302
32 GF Score
Price ¥36.47
! 2 Warning Signs
View Full Analysis

What is Hinova Pharmaceuticals Tax Provision?

Hinova Pharmaceuticals SHSE:688302 -4.23% 32 Tax Provision is ¥-0.00 Mil as of Mar. 2026. GuruFocus rates SHSE:688302 with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Hinova Pharmaceuticals's tax provision for the three months ended in Mar. 2026 was ¥-0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.00 Mil.

Hinova Pharmaceuticals Tax Provision Historical Data

* Premium members only.

The historical data trend for Hinova Pharmaceuticals's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hinova Pharmaceuticals Tax Provision Chart

Hinova Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial 0.00 0.00 -0.02 -0.01 -0.00

Hinova Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 -0.00 0.00 -0.00
SHSE:688302
32GF Score
Hinova Pharmaceuticals Inc SHSE:688302
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hinova Pharmaceuticals Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ¥-0.00 Mil mean?
Hinova Pharmaceuticals (SHSE:688302) has a Tax Provision of ¥-0.00 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Hinova Pharmaceuticals and its competitors.
Is Hinova Pharmaceuticals' Tax Provision too high?
Hinova Pharmaceuticals' current Tax Provision is ¥-0.00 Mil. Overall, Hinova Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Tax Provision compare to VRTX and REGN?
Hinova Pharmaceuticals' Tax Provision of ¥-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Hinova Pharmaceuticals and its competitors. Hinova Pharmaceuticals's current Tax Provision is ¥-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Tax Provision of ¥-0.00 Mil. The current Tax Provision is ¥-0.00 Mil. Hinova Pharmaceuticals' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Tax Provision is ¥-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hinova Pharmaceuticals Business Description

Address No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
32GF Score

Get the complete analysis for SHSE:688302

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.47
Price